S C Piscitelli1, M J Wells, J A Metcalf, M Baseler, R Stevens, R T Davey. 1. Department of Pharmacy, Warren G. Magnuson Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. spisc@nih.gov
Abstract
STUDY OBJECTIVES: To assess the pharmacokinetics and pharmacodynamics of subcutaneously administered interleukin-2 (IL-2) in patients infected with the human immunodeficiency virus (HIV). DESIGN: Open, dose-escalating phase I clinical trial. SETTING: Government research hospital. PATIENTS: Eighteen patients infected with HIV. INTERVENTIONS: Recombinant IL-2 at dosages of 12, 15, or 18 MIU/day was administered subcutaneously once or twice/day for 5 consecutive days every 2 months. A total of 28 cycles of therapy were included in the analysis. MEASUREMENTS AND MAIN RESULTS: Concentrations of IL-2 in serum were determined by a commercial enzyme-linked immunosorbent assay. Interleukin-2 was well absorbed, with peak concentrations from 21.9-112.9 IU/ml. Absorption was slow, with mean (+/- SD) time to maximum of 4.4 +/- 1.8 hours and a lag time of 26.9 +/- 13.7 minutes. Elimination half-life was 3.3 +/- 0.9 hours. The concentrations had wide variability both within and among patients. Levels of tumor necrosis factor-alpha were increased. Maximum body temperature and systemic side effects were associated with peak serum levels. CONCLUSION: Interleukin-2 is well absorbed after subcutaneous injection in HIV-infected patients, and that route of administration is an alternative to intravenous infusions.
STUDY OBJECTIVES: To assess the pharmacokinetics and pharmacodynamics of subcutaneously administered interleukin-2 (IL-2) in patients infected with the human immunodeficiency virus (HIV). DESIGN: Open, dose-escalating phase I clinical trial. SETTING: Government research hospital. PATIENTS: Eighteen patients infected with HIV. INTERVENTIONS: Recombinant IL-2 at dosages of 12, 15, or 18 MIU/day was administered subcutaneously once or twice/day for 5 consecutive days every 2 months. A total of 28 cycles of therapy were included in the analysis. MEASUREMENTS AND MAIN RESULTS: Concentrations of IL-2 in serum were determined by a commercial enzyme-linked immunosorbent assay. Interleukin-2 was well absorbed, with peak concentrations from 21.9-112.9 IU/ml. Absorption was slow, with mean (+/- SD) time to maximum of 4.4 +/- 1.8 hours and a lag time of 26.9 +/- 13.7 minutes. Elimination half-life was 3.3 +/- 0.9 hours. The concentrations had wide variability both within and among patients. Levels of tumor necrosis factor-alpha were increased. Maximum body temperature and systemic side effects were associated with peak serum levels. CONCLUSION:Interleukin-2 is well absorbed after subcutaneous injection in HIV-infectedpatients, and that route of administration is an alternative to intravenous infusions.
Authors: P De Paoli; S Zanussi; L Caggiari; M T Bortolin; M D'Andrea; C Simonelli; U Tirelli Journal: J Clin Immunol Date: 1999-09 Impact factor: 8.317
Authors: Jordan S Orange; Sumita Roy-Ghanta; Emily M Mace; Saumya Maru; Gregory D Rak; Keri B Sanborn; Anders Fasth; Rushani Saltzman; Allison Paisley; Linda Monaco-Shawver; Pinaki P Banerjee; Rahul Pandey Journal: J Clin Invest Date: 2011-03-07 Impact factor: 14.808
Authors: Charles J M Bell; Yongliang Sun; Urszula M Nowak; Jan Clark; Sarah Howlett; Marcin L Pekalski; Xin Yang; Oliver Ast; Inja Waldhauer; Anne Freimoser-Grundschober; Ekkehard Moessner; Pablo Umana; Christian Klein; Ralf J Hosse; Linda S Wicker; Laurence B Peterson Journal: J Autoimmun Date: 2014-10-30 Impact factor: 7.094